Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 10/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | MAOB | P27338 | 4/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | BCHE | P06276 | 2/20 | 0.75 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.75 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.75 |
| ▸ | ACHE | P22303 | 1/20 | 0.75 |
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.75 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.68 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.66 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.66 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363680 | 1.00 | CYP1B1 (0.75) | CYP1B1MAPTMAOBLMNABCHE | |
| SCHEMBL10033954 | 0.93 | CYP1B1 (0.75) | CYP1B1MAPTMAOBLMNABCHE | |
| SCHEMBL1390167 | 0.93 | CYP1B1 (0.75) | CYP1B1MAPTMAOBLMNABCHE | |
| Chalcone SCHEMBL10782589 | 0.91 | CYP1B1 (0.79) | CYP1B1MAPTMAOBLMNABCHE | |
| Chalcone SCHEMBL10782584 | 0.91 | CYP1B1 (0.79) | CYP1B1MAPTMAOBLMNABCHE | |
| SCHEMBL6934856 | 0.90 | CYP1B1 (0.70) | CYP1B1MAPTMAOBLMNABCHE | |
| SCHEMBL6934854 | 0.90 | CYP1B1 (0.70) | CYP1B1MAPTMAOBLMNABCHE | |
| Chalcone SCHEMBL28249237 | 0.88 | CYP1B1 (0.96) | CYP1B1MAPTMAOBLMNABCHE | |
| Chalcone SCHEMBL28249238 | 0.88 | CYP1B1 (0.96) | CYP1B1MAPTMAOBLMNABCHE | |
| SCHEMBL9915665 | 0.86 | CYP1B1 (0.91) | CYP1B1MAPTMAOBLMNABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0476658-B1 | 1-Phenyl-3-phenyl-2-propyne-1-ones | MERRELL DOW PHARMA (US) | 1995-11-15 | — | — | EP | claimed |
| WO-2007074238-A2 | NOVEL N-ALK-(E)-YLIDENE-N'-PYRIMIDIN-2-YL HYDRAZINE DERIVATIVES AND USE THEREOF AS CYTOPROTECTIVE DRUGS | TROPHOS (FR) | 2007-07-05 | — | — | WO | disclosed |
| US-6774127-B2 | TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2004-08-10 | — | — | US | disclosed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-14 | — | — | US | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1023066-A4 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1023066-A1 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-02 | — | — | EP | disclosed |
| EP-0476646-B1 | Calcium uptake inhibitors | MERRELL PHARMA INC (US) | 1997-06-04 | — | — | EP | disclosed |
| US-5500429-A | CARDIOVASCULAR | MERRELL PHARMACEUTICALS INC. (US) | 1996-03-19 | — | — | US | disclosed |
| EP-0476658-B1 | 1-Phenyl-3-phenyl-2-propyne-1-ones | MERRELL DOW PHARMA (US) | 1995-11-15 | — | — | EP | disclosed |
| US-5446068-A | Antiinflammatory agent | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-5409942-A | Administering 1-phenyl-3-aryl-2-propyne-1-ones compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| US-5248825-A | Aromatic ketones containing triple bond | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-09-28 | — | — | US | disclosed |
| US-5223518-A | Controlling intake in leukocytes and platelets | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0476646-A1 | Calcium uptake inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1992-03-25 | — | — | EP | disclosed |
| EP-0476645-A1 | Calcium uptake inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-03-25 | — | — | EP | disclosed |
| EP-0476658-A1 | 1-Phenyl-3-phenyl-2-propyne-1-ones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | PDXK, COQ8A, PDK3 | CYP1B1 1207/4885MAPT 1088/4885MAOB 2903/4885 |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | CYP1B1 115/4885MAPT 4093/4885MAOB 1221/4885 |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | MAPKAPK2, MAPKAPK3, MAPKAPK5 | CYP1B1 4255/4885MAPT 2568/4885MAOB 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.